Clinicians typically classify meningiomas—the most common type of brain tumor—into three grades, ranging from slow-growing to ...

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) comprise approximately 10% of the HIV drug market worldwide, and efavirenz leads this class with $680 million annual sales in the United ...

Reverse transcriptase is responsible for converting viral RNA into DNA via its dual functions – the DNA polymerase and RNase H activities – making it an attractive and multifaceted target.

Read the latest data on resistance associated with reverse transcriptase inhibitors in these summaries from the 12th International HIV Drug Resistance Workshop.

In this issue of hLife, the team led by Prof. Min Wang from Ocean University of China systematically mined and characterized the diversity of viral reverse transcriptases from global metagenomic ...

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.

Merck’s once-monthly oral HIV prevention pill, MK-8527, advances to Phase III and may offer an accessible PrEP option in the future.

Use of nucleoside reverse transcriptase inhibitors (NRTIs) is associated with a significantly lower risk of developing Alzheimer disease (AD), according to findings published in Alzheimer’s & Dementia ...

HIV-1 Reverse Transcriptase and Integrase Inhibitors Publication Trend The graph below shows the total number of publications each year in HIV-1 Reverse Transcriptase and Integrase Inhibitors.